BrainStorm Cell Therapeutics

Update in progress

BCLI (OTC Markets OTCQB)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Brainstorm Cell Therapeutics is a biotechnology company developing autologous cellular therapies for neurodegenerative diseases. Its NurOwn platform uses a patient’s own bone marrow–derived mesenchymal stem cells cultured to secrete neurotrophic factors that modulate neuroinflammation and support neuronal survival and function. NurOwn has completed Phase IIIb for ALS and Phase II for progressive MS, with research in Alzheimer's and other diseases. Founded 2000, based in New York.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive